Table 2.
Comparison of the study group and the control group in terms of sclerostin and IL-6 concentrations in plasma at three measurement points (baseline, month 3, month 6).
| Variable | Observation Period | Study Group (n = 34) | Control Group (n = 31) | p-Value | ||||
|---|---|---|---|---|---|---|---|---|
| X (SD) | Range | Me | X (SD) | Range | Me | |||
| Sclerostin [pg/mL] | E0 | 548.1 (382.2) | 155.9–1735.4 | 472.8 | 391.8 (94.4) | 243.9–597.7 | 365.4 | 0.2170 |
| E3 | 432.4 (282.9) | 148.0–1553.4 | 387.4 | 404.8 (104.5) | 232.1–619.4 | 411.2 | 0.5501 | |
| E6 | 415.0 (208.5) | 147.8–1032.4 | 396.5 | 392.1 (85.2) | 249.0–567.6 | 388.0 | 0.9581 | |
| Interleukin 6 [pg/mL] | E0 | 9.0 (12.8) | 1.2–56.8 | 4.2 | 2.7 (7.7) | 0.2–43.9 | 1.0 | 0.0000 * |
| E3 | 10.4 (5.9) | 1.2–68.4 | 4.8 | 2.2 (5.6) | 0.1–32.1 | 1.2 | 0.0000 * | |
| E6 | 9.0 (12.3) | 1.1–51.6 | 5.2 | 2.4 (6.7) | 0.3–38.3 | 1.1 | 0.0000 * | |
X—arithmetic mean; SD—standard deviation; Me—median; Range—(minimum–maximum); E0—measurement at study entry; E3—measurement after 3 months of the study; E6—measurement after 6 months of the study; p-value—statistical significance; *—statistically significant parameter; n–number.